NASDAQ:INO - Inovio Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$4.99 -0.05 (-0.99 %)
(As of 05/21/2018 01:14 AM ET)
Previous Close$4.99
Today's Range$4.91 - $5.12
52-Week Range$3.76 - $9.86
Volume963,149 shs
Average Volume1.01 million shs
Market Capitalization$453.90 million
P/E Ratio-4.58
Dividend YieldN/A
Beta2.52

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Receive INO News and Ratings via Email

Sign-up to receive the latest news and ratings for INO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:INO
CUSIPN/A
Phone267-440-4200

Debt

Debt-to-Equity RatioN/A
Current Ratio2.41
Quick Ratio2.41

Price-To-Earnings

Trailing P/E Ratio-4.58
Forward P/E Ratio-3.67
P/E GrowthN/A

Sales & Book Value

Annual Sales$42.22 million
Price / Sales10.75
Cash FlowN/A
Price / CashN/A
Book Value$1.24 per share
Price / Book4.02

Profitability

EPS (Most Recent Fiscal Year)($1.09)
Net Income$-88,200,000.00
Net Margins-292.06%
Return on Equity-72.04%
Return on Assets-53.90%

Miscellaneous

Employees280
Outstanding Shares90,960,000

Inovio Pharmaceuticals (NASDAQ:INO) Frequently Asked Questions

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

How often does Inovio Pharmaceuticals pay dividends? What is the dividend yield for Inovio Pharmaceuticals?

Inovio Pharmaceuticals announced a monthly dividend on Thursday, September 21st. Investors of record on Friday, September 29th will be paid a dividend of $0.069 per share on Monday, October 16th. This represents a $0.83 annualized dividend and a yield of 16.59%. The ex-dividend date is Thursday, September 28th. View Inovio Pharmaceuticals' Dividend History.

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Shares of Inovio Pharmaceuticals reverse split on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals Inc (NASDAQ:INO) announced its quarterly earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.14) by $0.22. The biopharmaceutical company had revenue of $1.53 million for the quarter, compared to the consensus estimate of $7.50 million. Inovio Pharmaceuticals had a negative return on equity of 72.04% and a negative net margin of 292.06%. During the same period in the prior year, the business posted ($0.31) EPS. View Inovio Pharmaceuticals' Earnings History.

What price target have analysts set for INO?

7 Wall Street analysts have issued twelve-month price objectives for Inovio Pharmaceuticals' shares. Their forecasts range from $8.00 to $14.00. On average, they expect Inovio Pharmaceuticals' stock price to reach $12.00 in the next twelve months. View Analyst Ratings for Inovio Pharmaceuticals.

What are Wall Street analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Inovio’s progress with its lead pipeline candidate, VGX-3100, for treatment of cervical dysplasia is encouraging. We are also positive on the company’s collaboration with big pharma companies like Regeneron, AstraZeneca, and the University of Pennsylvania, as it lends Inovio with their expertise. Moreover, the company’s targeted cervical cancer market holds untapped potential. On the flip side, as the company has no approved product in its portfolio, its excessive dependence on its partners for funding the development of its pipeline candidates is concerning. Moreover, due to early/mid-stage nature of its pipeline, the candidates are several steps away from entering the market. Shares of the company have underperformed the industry in the last one year." (1/9/2018)
  • 2. Maxim Group analysts commented, "Inovio announced an amended agreement with ApolloBio (NEEQ: 430187) to develop and commercialize VGX-3100 for precancerous HPV (human papillomavirus) infections and dysplasias (cervical, vulvar, anal) in Greater China (China, Hong Kong, Macao, Taiwan, potentially Korea too). Inovio will receive an upfront payment of $23M plus milestones and royalties. The deal is expected to close in 1Q18." (1/2/2018)

Who are some of Inovio Pharmaceuticals' key competitors?

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:
  • Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director (Age 48)
  • Peter D. Kies, Chief Financial Officer (Age 53)
  • Niranjan Y. Sardesai Ph.D., Chief Operating Officer (Age 49)
  • Mark L. Bagarazzi M.D., Chief Medical Officer (Age 56)
  • Avtar S. Dhillon M.D., Non-Executive Chairman of the Board (Age 56)
  • George W. Bickerstaff III, Director (Age 62)
  • David B. Weiner, Director (Age 61)
  • Wendy L. Yarno, Director (Age 63)
  • Simon X. Benito, Independent Director (Age 72)

Has Inovio Pharmaceuticals been receiving favorable news coverage?

News coverage about INO stock has trended somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Inovio Pharmaceuticals earned a media sentiment score of 0.07 on Accern's scale. They also gave news articles about the biopharmaceutical company an impact score of 47.59 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Inovio Pharmaceuticals' major shareholders?

Inovio Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.15%), Wasatch Advisors Inc. (2.83%), Northern Trust Corp (1.10%), Guggenheim Capital LLC (0.55%), UBS Group AG (0.49%) and Schwab Charles Investment Management Inc. (0.45%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Which institutional investors are selling Inovio Pharmaceuticals stock?

INO stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Wasatch Advisors Inc., Barclays PLC and Northern Trust Corp. Company insiders that have sold Inovio Pharmaceuticals company stock in the last year include David B Weiner, Jong Joseph Kim and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.

Which institutional investors are buying Inovio Pharmaceuticals stock?

INO stock was acquired by a variety of institutional investors in the last quarter, including Guggenheim Capital LLC, UBS Group AG, Schwab Charles Investment Management Inc., New York State Common Retirement Fund and Swiss National Bank. View Insider Buying and Selling for Inovio Pharmaceuticals.

How do I buy shares of Inovio Pharmaceuticals?

Shares of INO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of INO stock can currently be purchased for approximately $4.99.

How big of a company is Inovio Pharmaceuticals?

Inovio Pharmaceuticals has a market capitalization of $453.90 million and generates $42.22 million in revenue each year. The biopharmaceutical company earns $-88,200,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Inovio Pharmaceuticals employs 280 workers across the globe.

How can I contact Inovio Pharmaceuticals?

Inovio Pharmaceuticals' mailing address is 660 WEST GERMANTOWN PIKE SUITE 110, PLYMOUTH MEETING PA, 19462. The biopharmaceutical company can be reached via phone at 267-440-4200 or via email at [email protected]


MarketBeat Community Rating for Inovio Pharmaceuticals (INO)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  404 (Vote Outperform)
Underperform Votes:  220 (Vote Underperform)
Total Votes:  624
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe INO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Inovio Pharmaceuticals (NASDAQ:INO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
7 Wall Street analysts have issued ratings and price targets for Inovio Pharmaceuticals in the last 12 months. Their average twelve-month price target is $12.00, suggesting that the stock has a possible upside of 140.48%. The high price target for INO is $14.00 and the low price target for INO is $8.00. There are currently 7 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.002.802.802.80
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
7 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
8 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $12.00$20.10$19.80$20.20
Price Target Upside: 140.48% upside310.20% upside373.68% upside336.29% upside

Inovio Pharmaceuticals (NASDAQ:INO) Consensus Price Target History

Price Target History for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/16/2018HC WainwrightSet Price TargetBuy$13.00MediumView Rating Details
5/10/2018Maxim GroupSet Price TargetBuy$8.00HighView Rating Details
3/15/2018Royal Bank of CanadaBoost Price TargetOutperform$11.00 ➝ $14.00HighView Rating Details
10/6/2017CitigroupInitiated CoverageBuy$10.00N/AView Rating Details
7/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$14.00MediumView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies GroupReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
5/25/2016National Bank FinancialDowngradeOutperform Market Weight ➝ Sector Perform Market WeightN/AView Rating Details
(Data available from 5/21/2016 forward)

Earnings

Inovio Pharmaceuticals (NASDAQ:INO) Earnings History and Estimates Chart

Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.36 EPS
Next Year EPS Consensus Estimate: $-1.26 EPS

Inovio Pharmaceuticals (NASDAQ INO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2018Q1 2018($0.14)($0.36)$7.50 million$1.53 millionViewN/AView Earnings Details
3/14/2018Q4 17($0.30)($0.24)$9.13 million$8.80 millionViewListenView Earnings Details
11/8/2017Q3 17($0.25)($0.40)$10.27 million$2.60 millionViewN/AView Earnings Details
8/8/2017Q2 17($0.21)($0.13)$16.29 million$20.41 millionViewListenView Earnings Details
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/15/2014$0.22$0.22$4.63 million$4.66 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
5/7/2014$0.20$0.23$4.63 million$4.89 millionViewN/AView Earnings Details
3/22/2014$0.20$0.24ViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
8/9/2013Q2 2013($0.08)($0.20)$1.60 million$0.79 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.16)$1.45 million$1.46 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.16)($0.08)ViewN/AView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
8/9/2012Q2 2012($0.16)($0.17)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.16)($0.19)ViewN/AView Earnings Details
3/15/2012Q4 2011($0.20)($0.16)ViewN/AView Earnings Details
11/7/2011Q3 2011($0.12)($0.15)ViewN/AView Earnings Details
8/8/2011Q2 2011($0.20)($0.09)ViewN/AView Earnings Details
5/11/2011Q1 2011($0.16)($0.09)ViewN/AView Earnings Details
3/17/2011Q4 2010($0.16)($0.24)ViewN/AView Earnings Details
11/15/2010Q3 2010($0.12)($0.06)ViewN/AView Earnings Details
8/16/2010Q2 2010($0.08)($0.30)ViewN/AView Earnings Details
5/17/2010Q1 2010($0.16)($0.13)ViewN/AView Earnings Details
3/29/2010Q4 2009($0.20)($0.28)ViewN/AView Earnings Details
11/16/2009Q3 2009($0.20)($0.12)ViewN/AView Earnings Details
8/19/2009Q2 2009($0.24)($0.24)ViewN/AView Earnings Details
5/14/2009Q1 2009($0.32)ViewN/AView Earnings Details
3/31/2009Q4 2008($0.32)ViewN/AView Earnings Details
11/7/2008Q3 2008($0.21)ViewN/AView Earnings Details
8/7/2008Q2 2008($0.37)ViewN/AView Earnings Details
5/9/2008Q1 2008($0.28)ViewN/AView Earnings Details
3/17/2008Q4 2007($0.44)($0.09)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Inovio Pharmaceuticals (NASDAQ:INO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/21/2017Monthly$0.06909/28/20179/29/201710/16/2017
8/22/2017Monthly$0.06908/29/20178/31/20179/15/2017
7/25/2017Monthly$0.06907/27/20177/31/20178/15/2017
6/23/2017Monthly$0.06906/28/20176/30/20177/17/2017
(Data available from 1/1/2013 forward)

Insider Trades

Inovio Pharmaceuticals (NASDAQ INO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 9.40%
Institutional Ownership Percentage: 31.34%
Insider Trading History for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Trading History for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ INO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2018David B WeinerDirectorSell9,000$4.91$44,190.00758,956View SEC Filing  
4/12/2018Jong Joseph KimCEOSell103,750$5.14$533,275.002,395,557View SEC Filing  
4/12/2018Simon X BenitoDirectorSell3,750$5.23$19,612.5031,548View SEC Filing  
5/25/2017David B WeinerDirectorSell8,000$8.00$64,000.00740,956View SEC Filing  
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.202,164,887View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00142,291View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.0070,234View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00142,291View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.5024,048View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00127,291View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.0032,000View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.005,965,809View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00655,864View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Inovio Pharmaceuticals (NASDAQ INO) News Headlines

Source:
DateHeadline
Inovio Pharmaceuticals (INO) Upgraded to "Hold" at ValuEngineInovio Pharmaceuticals (INO) Upgraded to "Hold" at ValuEngine
www.americanbankingnews.com - May 18 at 11:20 PM
Inovio Pharmaceuticals (INO) Upgraded at BidaskClubInovio Pharmaceuticals (INO) Upgraded at BidaskClub
www.americanbankingnews.com - May 18 at 3:09 PM
Inovio Pharma (INO) Says Presentation at ASCO Show Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate CancerInovio Pharma (INO) Says Presentation at ASCO Show Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
www.streetinsider.com - May 17 at 3:11 PM
Inovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate CancerInovio Pharmaceuticals Demonstrates PSA Stabilizing Effect of INO-5150 Immunotherapy in Phase 1b Study for Prostate Cancer
finance.yahoo.com - May 17 at 3:11 PM
Inovio Pharmaceuticals (INO) Earns "Buy" Rating from HC WainwrightInovio Pharmaceuticals (INO) Earns "Buy" Rating from HC Wainwright
www.americanbankingnews.com - May 16 at 1:49 PM
Investors Purchase Large Volume of Call Options on Inovio Pharmaceuticals (INO)Investors Purchase Large Volume of Call Options on Inovio Pharmaceuticals (INO)
www.americanbankingnews.com - May 16 at 6:36 AM
Inovios HIV vaccine shows positive effect in early-stage study; shares up 8% premarketInovio's HIV vaccine shows positive effect in early-stage study; shares up 8% premarket
seekingalpha.com - May 16 at 5:01 AM
Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses ...Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses ...
globenewswire.com - May 15 at 3:01 PM
BRIEF-Inovio Says HIV Vaccine Maintained Immune Responses One Year After Start Of TrialBRIEF-Inovio Says HIV Vaccine Maintained Immune Responses One Year After Start Of Trial
www.reuters.com - May 15 at 3:01 PM
Inovio Pharma (INO) Says HIV Vaccine Sustained Durable Memory Responses Measured One Year After Start of ...Inovio Pharma (INO) Says HIV Vaccine Sustained Durable Memory Responses Measured One Year After Start of ...
www.streetinsider.com - May 15 at 3:01 PM
Inovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical TrialInovio HIV Vaccine, Which Generated Near 100% Immune Responses, Sustained Durable Memory Responses Measured One Year After The Start of Clinical Trial
finance.yahoo.com - May 15 at 3:01 PM
Form 4 INOVIO PHARMACEUTICALS, For: May 11 Filed by: DHILLON AVTAR SForm 4 INOVIO PHARMACEUTICALS, For: May 11 Filed by: DHILLON AVTAR S
www.streetinsider.com - May 15 at 5:19 AM
Inovio Pharmaceuticals (INO) Upgraded at ValuEngineInovio Pharmaceuticals (INO) Upgraded at ValuEngine
www.americanbankingnews.com - May 11 at 9:23 PM
Inovios (INO) Q1 Loss Wider than Expected, Shares DownInovio's (INO) Q1 Loss Wider than Expected, Shares Down
www.nasdaq.com - May 11 at 5:19 AM
Inovio Pharmaceuticals (INO) Releases Quarterly  Earnings Results, Misses Estimates By $0.22 EPSInovio Pharmaceuticals (INO) Releases Quarterly Earnings Results, Misses Estimates By $0.22 EPS
www.americanbankingnews.com - May 10 at 11:33 PM
Inovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright AnalystsInovio Pharmaceuticals (INO) Given a $13.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - May 10 at 7:57 PM
Maxim Group Analysts Give Inovio Pharmaceuticals (INO) a $8.00 Price TargetMaxim Group Analysts Give Inovio Pharmaceuticals (INO) a $8.00 Price Target
www.americanbankingnews.com - May 10 at 7:51 PM
Inovio Pharmaceuticals Q1 18 Earnings Conference Call At 4:30 PM ETInovio Pharmaceuticals Q1 18 Earnings Conference Call At 4:30 PM ET
www.nasdaq.com - May 10 at 3:09 PM
BRIEF-Inovio Pharmaceuticals Q1 Loss Per Share $0.36BRIEF-Inovio Pharmaceuticals Q1 Loss Per Share $0.36
www.reuters.com - May 10 at 3:09 PM
Inovio Pharmaceuticals (INO) PT Lowered to $13 at RBC CapitalInovio Pharmaceuticals (INO) PT Lowered to $13 at RBC Capital
www.streetinsider.com - May 10 at 3:09 PM
Edited Transcript of INO earnings conference call or presentation 9-May-18 8:30pm GMTEdited Transcript of INO earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 3:09 PM
Benzingas Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimers Trial ResultsBenzinga's Daily Biotech Pulse: ARMO Skyrockets On Eli Lilly Deal, Akcea Meets FDA Panel, vTv Alzheimer's Trial Results
finance.yahoo.com - May 10 at 3:09 PM
Inovio's (INO) Q1 Loss Wider than Expected, Shares DownInovio's (INO) Q1 Loss Wider than Expected, Shares Down
finance.yahoo.com - May 10 at 3:09 PM
Inovios (INO) CEO Joseph Kim on Q1 2018 Results - Earnings Call TranscriptInovio's (INO) CEO Joseph Kim on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 5:01 AM
BRIEF-Inovio Pharmaceuticals Says For Qtr Ended March 31, Net Loss Per Share Was $0.36BRIEF-Inovio Pharmaceuticals Says For Qtr Ended March 31, Net Loss Per Share Was $0.36
www.reuters.com - May 10 at 5:01 AM
Inovio Pharmaceuticals misses by $0.22, misses on revenueInovio Pharmaceuticals misses by $0.22, misses on revenue
seekingalpha.com - May 10 at 5:01 AM
Inovio: 1Q Earnings SnapshotInovio: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 5:01 AM
Inovio Pharmaceuticals Reports 2018 First Quarter Financial ResultsInovio Pharmaceuticals Reports 2018 First Quarter Financial Results
finance.yahoo.com - May 10 at 5:01 AM
Inovio Pharmaceuticals Inc (INO) Receives Average Rating of "Buy" from BrokeragesInovio Pharmaceuticals Inc (INO) Receives Average Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 6 at 1:44 AM
ValuEngine Upgrades Inovio Pharmaceuticals (INO) to SellValuEngine Upgrades Inovio Pharmaceuticals (INO) to Sell
www.americanbankingnews.com - May 3 at 10:34 PM
Inovio Pharmaceuticals (INO) Set to Announce Earnings on TuesdayInovio Pharmaceuticals (INO) Set to Announce Earnings on Tuesday
www.americanbankingnews.com - May 1 at 7:51 AM
Is Inovio Pharmaceuticals, Inc. (INO) a Buy?Is Inovio Pharmaceuticals, Inc. (INO) a Buy?
finance.yahoo.com - April 30 at 3:09 PM
Inovio Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018Inovio Pharmaceuticals to Report First Quarter 2018 Financial Results on May 9, 2018
finance.yahoo.com - April 30 at 3:09 PM
Insider Selling: Inovio Pharmaceuticals Inc (INO) Director Sells 9,000 Shares of StockInsider Selling: Inovio Pharmaceuticals Inc (INO) Director Sells 9,000 Shares of Stock
www.americanbankingnews.com - April 19 at 7:52 PM
Inovio Pharmaceuticals Inc (INO) Director Sells $19,612.50 in StockInovio Pharmaceuticals Inc (INO) Director Sells $19,612.50 in Stock
www.americanbankingnews.com - April 13 at 7:27 PM
Inovio Pharmaceuticals Inc (INO) CEO Jong Joseph Kim Sells 103,750 SharesInovio Pharmaceuticals Inc (INO) CEO Jong Joseph Kim Sells 103,750 Shares
www.americanbankingnews.com - April 13 at 7:11 PM
Why Is Inovio (INO) Up 6.6% Since Its Last Earnings Report?Why Is Inovio (INO) Up 6.6% Since Its Last Earnings Report?
finance.yahoo.com - April 13 at 3:12 PM
Inovio Pharmaceuticals (INO) Given a $13.00 Price Target at HC WainwrightInovio Pharmaceuticals (INO) Given a $13.00 Price Target at HC Wainwright
www.americanbankingnews.com - April 12 at 11:17 AM
BLCM Surges As FDA Lifts Hold, SMMT Awaits Data In Q3, GEN Exits TexasBLCM Surges As FDA Lifts Hold, SMMT Awaits Data In Q3, GEN Exits Texas
www.nasdaq.com - April 12 at 5:15 AM
Inovio Pharmaceuticals (INO) PT Set at $12.00 by Maxim GroupInovio Pharmaceuticals (INO) PT Set at $12.00 by Maxim Group
www.americanbankingnews.com - April 11 at 11:52 PM
Inovio Pharma (INO) Awarded up to $56M from CEPIInovio Pharma (INO) Awarded up to $56M from CEPI
www.streetinsider.com - April 11 at 3:13 PM
Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERSInovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS
globenewswire.com - April 11 at 3:13 PM
$56 million deal: Inovio secures Coalition funding for vaccine candidates$56 million deal: Inovio secures Coalition funding for vaccine candidates
www.bizjournals.com - April 11 at 3:13 PM
Inovio Pharmaceuticals (INO) Given a $8.00 Price Target at Maxim GroupInovio Pharmaceuticals (INO) Given a $8.00 Price Target at Maxim Group
www.americanbankingnews.com - April 11 at 12:37 PM
Inovio Pharmaceuticals Inc (INO) Given Average Recommendation of "Buy" by BrokeragesInovio Pharmaceuticals Inc (INO) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - April 11 at 1:24 AM
Inovio Pharmaceuticals (INO) Rating Increased to Sell at ValuEngineInovio Pharmaceuticals (INO) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM
Inovio Pharmaceuticals (INO) Presents At H. C. Wainwright Global Life Sciences Conference - SlideshowInovio Pharmaceuticals (INO) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
seekingalpha.com - April 10 at 3:01 PM
Inovio Pharmaceuticals (INO) Stock Rating Lowered by Zacks Investment ResearchInovio Pharmaceuticals (INO) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:58 PM
HC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price TargetHC Wainwright Analysts Give Inovio Pharmaceuticals (INO) a $13.00 Price Target
www.americanbankingnews.com - April 6 at 11:31 PM
Inovio Pharmaceuticals (INO) Coverage Initiated by Analysts at Royal Bank of CanadaInovio Pharmaceuticals (INO) Coverage Initiated by Analysts at Royal Bank of Canada
www.americanbankingnews.com - April 6 at 4:15 PM

SEC Filings

Inovio Pharmaceuticals (NASDAQ:INO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Inovio Pharmaceuticals (NASDAQ:INO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Inovio Pharmaceuticals (NASDAQ INO) Stock Chart for Monday, May, 21, 2018

Loading chart…

This page was last updated on 5/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.